IMCD N.V. (0QVU.IL)
| Previous close | 141.27 |
| Open | 140.85 |
| Bid | 137.80 x 0 |
| Ask | 144.35 x 0 |
| Day's range | 140.80 - 142.20 |
| 52-week range | 109.05 - 168.95 |
| Volume | |
| Avg. volume | 61,599 |
| Market cap | 8.614B |
| Beta (5Y monthly) | 0.95 |
| PE ratio (TTM) | 27.93 |
| EPS (TTM) | 5.06 |
| Earnings date | 02 Aug 2024 |
| Forward dividend & yield | 2.37 (2.12%) |
| Ex-dividend date | 28 Apr 2023 |
| 1y target est | N/A |
Simply Wall St.IMCD's (AMS:IMCD) five-year total shareholder returns outpace the underlying earnings growth
IMCD N.V. ( AMS:IMCD ) shareholders have seen the share price descend 13% over the month. But that doesn't change the...
Globe NewswireIMCD reports EBITA of EUR 127 million in the first three months of 2024
IMCD_logo Logo IMCD Rotterdam, The Netherlands (26 April 2024) - IMCD N.V. (“IMCD” or “Company”), a global leading distribution partner, and formulator of speciality chemicals and ingredients, today announces its first three months 2024 results. HIGHLIGHTS Gross profit of EUR 295 million (on a constant currency basis, equal to the first three months of 2023)Operating EBITA decline of 15% to EUR 127 million (-13% on a constant currency basis)Free cash flow of EUR 106 million (first three months o
GlobeNewswireIMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma
Photo_IMCD Spain expands its Pharmaceuticals presence with the acquisition of Cobapharma Photographed from left to right:•Cristina Marti, Director API Sales and Strategy, IMCD Group•Gianluca Galimberti, General Manager, Cobapharma•Tess Hendriks, Legal Counsel M&A, IMCD Group•Fenna van Zanten, Director M&A, IMCD Group•Jose Alcover, Managing Director, IMCD Iberia & Maghreb ROTTERDAM, The Netherlands 24 April 2024 – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and
